Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.

Olivier HermineXavier MarietteRaphael PorcherMatthieu Resche-RigonPierre-Louis TharauxPhilippe Ravaudnull null

Published in: The European respiratory journal (2022)

In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.

Keyphrases

end stage renal disease
sars cov
coronavirus disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
quality improvement
respiratory syndrome coronavirus